Immuneering (IMRX)
(Delayed Data from NSDQ)
$1.87 USD
+0.01 (0.54%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $1.86 -0.01 (-0.53%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
IMRX 1.87 +0.01(0.54%)
Will IMRX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for IMRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMRX
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
IMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
Other News for IMRX
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
Immuneering rises on orphan drug designation for treatment of pancreatic cancer
Immuneering granted Orphan Drug Designation for IMM-1-104
Immuneering treatment of pancreatic cancer granted FDA orphan status